# Blenrep (belantamab mafodotin) combinations in multiple myeloma application accepted for review by the European Medicines Agency
Canonical URL: https://biopharmsignal.com/news/GSK/blenrep-belantamab-mafodotin-combinations-in-multiple-myeloma-application-accepted-for-review-by-the-european-medicines-agency
Ticker: GSK
Company: GSK plc
Source: GSK plc
Published: 2024-07-19 06:08 EST
Original Source URL: https://www.gsk.com
## Summary

Regulatory submission supported by phase III head-to-head DREAMM-7 and DREAMM-8 trials

## Article Body
Regulatory submission supported by phase III head-to-head DREAMM-7 and DREAMM-8 trials
## Recent Company News
- 2026-07-29 09:08 EST — [Cabenuva demonstrates superiority to daily oral therapy in adolescents living with HIV, as ViiV Healthcare highlights new long-acting injectable data at AIDS 2026](https://biopharmsignal.com/news/GSK/cabenuva-demonstrates-superiority-to-daily-oral-therapy-in-adolescents-living-wi-f233257f) — Source: GSK plc
- 2026-07-28 12:05 EST — [GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK](https://biopharmsignal.com/news/GSK/gsk-to-establish-new-flagship-r-d-centre-on-cambridge-biomedical-campus-uk-6f2bb859) — Source: GSK plc
- 2026-07-28 12:00 EST — [GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026](https://biopharmsignal.com/news/GSK/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum-plans-ann-1d427d5e) — Source: GSK plc
- 2026-07-28 11:00 EST — [GSK’s licensor Hansoh Pharma announces positive results from a second phase III trial for Ris-Rez in China](https://biopharmsignal.com/news/GSK/gsk-s-licensor-hansoh-pharma-announces-positive-results-from-a-second-phase-iii--07f96324) — Source: GSK plc
- 2026-07-27 14:55 EST — [ViiV Healthcare’s 2-drug regimen Dovato is as effective as 3-drug regimen Biktarvy in first-of-its-kind head-to-head study in treatment-naïve adults living with HIV](https://biopharmsignal.com/news/GSK/viiv-healthcare-s-2-drug-regimen-dovato-is-as-effective-as-3-drug-regimen-biktar-781cde81) — Source: GSK plc
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)